Recurrence rates of Barrett’s esophagus and dysplasia in patients successfully treated with radiofrequency ablation vs. cryoballoon ablation: a comparative study
Endoscopy · 01.09.2025 · 57 (09) · 951-959
DOI: 10.1055/a-2598-6806 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Endoscopy, erschienen am 01.09.2025. Verfasst von Karan Sachdeva und 7 weiteren Autor:innen. Beteiligte Einrichtung: Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States. Hauptthemen laut MEDLINE: Barrett Esophagus, Cryosurgery, Radiofrequency Ablation, Catheter Ablation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Endoscopic eradication therapy (EET) is recommended for the management of dysplastic Barrett’s esophagus (BE) and intramucosal adenocarcinoma. Both radiofrequency (RFA) and cryoballoon ablation (CBA) can induce complete remission of intestinal metaplasia (CRIM). We aimed to compare long-term durability following CRIM in patients treated with RFA vs. CBA. We conducted a retrospective cohort study to analyze patient outcomes following EET with RFA or CBA at two referral centers. We measured and compared the recurrence rate of BE, with or without dysplasia, after CRIM, using Cox proportional hazard models and propensity score-matched analyses. Our secondary aim was to identify predictors of recurrence. 681 patients who achieved CRIM were included (RFA 610; CBA 71), with median follow-up of 4.1 years and 4.4 years following RFA and CBA, respectively. A multivariable model revealed a higher risk of any recurrence with RFA (hazard ratio [HR] 2.19, 95%CI 1.18–4.06; P = 0.01), but not dysplastic recurrence (HR 0.88, 95%CI 0.39–1.97; P = 0.75). However, a comparable risk of “any recurrence” was observed after excluding intestinal metaplasia of the gastroesophageal junction (HR 1.18, 95%CI 0.61–2.30; P = 0.62). Propensity score-matched analysis (54 cases in each group) showed that the two groups had comparable recurrence risk. Baseline maximum BE length was associated with a higher risk of any recurrence (HR 1.07; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States.
- Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, United States.
- Division of Gastroenterology, Rutgers University School of Medicine, New Brunswick, United States.
- Division of Gastroenterology, Long Island Jewish Medical Center, New Hyde Park, United States.
- Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, United States.
ORCID-Profile: Arvind J Trindade
Zitieren
APA
Sachdeva, K., Chandi, P. S., Verma, A., Dierkhising, R., Codipilly, D. C., Leggett, C. L., Trindade, A. J., & Iyer, P. G. (2025). Recurrence rates of Barrett’s esophagus and dysplasia in patients successfully treated with radiofrequency ablation vs. cryoballoon ablation: a comparative study. Endoscopy, 57(09), 951-959. https://doi.org/10.1055/a-2598-6806
Vancouver
Sachdeva K, Chandi PS, Verma A, Dierkhising R, Codipilly DC, Leggett CL, et al. Recurrence rates of Barrett’s esophagus and dysplasia in patients successfully treated with radiofrequency ablation vs. cryoballoon ablation: a comparative study. Endoscopy. 2025;57(09):951-959. doi:10.1055/a-2598-6806
BibTeX
@article{Sachdeva2025,
author = {Sachdeva, Karan and Chandi, Paras Singh and Verma, Anjul and Dierkhising, Ross and Codipilly, D Chamil and Leggett, Cadman L and Trindade, Arvind J and Iyer, Prasad G},
title = {Recurrence rates of Barrett’s esophagus and dysplasia in patients successfully treated with radiofrequency ablation vs. cryoballoon ablation: a comparative study},
journal = {Endoscopy},
year = {2025},
volume = {57},
number = {09},
pages = {951--959},
doi = {10.1055/a-2598-6806}
}
EUVIMED